Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics
By Colin Kellaher
Merck & Co. has agreed to license a potential cancer treatment from SciBrunch Therapeutics in a deal that could be worth more than $2 billion to the privately held clinical-stage biotechnology company.
Merck on Monday said the agreement gives the Rahway, N.J., drugmaker exclusive worldwide rights to develop, manufacture and commercialize SPR2015, an engineered inhibitor for one of the most prevalent mutant forms of the KRAS gene found in human cancers.
Merck said it is making a $400 million upfront payment to SciBrunch. The clinical-stage biotech company is also eligible to receive milestone payments associated to development, commercialization and other activities across multiple indications that could bring the total potential value of the transaction to $2.13 billion.
Merck said it will record a pretax charge of $400 million, or about 13 cents a share, in the third quarter related to the transaction, which has closed.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 28, 2026 07:38 ET (11:38 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States